Pharmacokinetics of promazine

I disposition in patients with acute viral hepatitis B

Oliver Y.‐P Hu, Hung‐Shang ‐S Tang, Tuzen‐Yan ‐Y Sheeng, Sung‐Chao ‐C Chen, San‐Kan ‐K Lee, Ping‐Hong ‐H Chung

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Concentrations of promazine in plasma, plasma water, red blood cells, and urine were measured after oral administration of the drug to six patients during and after apparent recovery from the acute phase of viral hepatitis B. None of the promazine pharmacokinetic parameters were significantly different during and after the acute phase; these parameters included clearance, free drug clearance, metabolic clearance, volume of distribution, distribution and elimination half‐life values, plasma protein binding, and per cent excreted in the urine. During the acute period of the illness, SGOP, SGPT, alkaline phosphatase, and total bilirubin were increased in all patients; they returned to within or near the upper limits or normal after recovery. Despite the unchanged promazine disposition, four out of six patients had more severe promazine side‐effects, such as sedation, postural hypotension, and dizziness during the acute phase of the illness. This study suggests that promazine disposition was not significantly altered as a consequence of viral hepatitis. However, the pharmoacodynamic effects of promazine were changed significantly. Care must be taken with patients who are taking promazine during the acute phase of viral hepatitis B.

Original languageEnglish
Pages (from-to)557-568
Number of pages12
JournalBiopharmaceutics & Drug Disposition
Volume11
Issue number7
DOIs
Publication statusPublished - Jan 1 1990
Externally publishedYes

Fingerprint

Promazine
Hepatitis B
Pharmacokinetics
Urine
Orthostatic Hypotension
Dizziness
Alanine Transaminase
Bilirubin
Protein Binding
Hepatitis
Alkaline Phosphatase
Oral Administration
Half-Life
Blood Proteins
Erythrocytes
Water

Keywords

  • Acute viral hepatitis
  • Pharmacokinetics
  • Promazine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Hu, O. Y. P., Tang, HS. S., Sheeng, TY. Y., Chen, SC. C., Lee, SK. K., & Chung, PH. H. (1990). Pharmacokinetics of promazine: I disposition in patients with acute viral hepatitis B. Biopharmaceutics & Drug Disposition, 11(7), 557-568. https://doi.org/10.1002/bdd.2510110702

Pharmacokinetics of promazine : I disposition in patients with acute viral hepatitis B. / Hu, Oliver Y.‐P; Tang, Hung‐Shang ‐S; Sheeng, Tuzen‐Yan ‐Y; Chen, Sung‐Chao ‐C; Lee, San‐Kan ‐K; Chung, Ping‐Hong ‐H.

In: Biopharmaceutics & Drug Disposition, Vol. 11, No. 7, 01.01.1990, p. 557-568.

Research output: Contribution to journalArticle

Hu, OYP, Tang, HSS, Sheeng, TYY, Chen, SCC, Lee, SKK & Chung, PHH 1990, 'Pharmacokinetics of promazine: I disposition in patients with acute viral hepatitis B', Biopharmaceutics & Drug Disposition, vol. 11, no. 7, pp. 557-568. https://doi.org/10.1002/bdd.2510110702
Hu, Oliver Y.‐P ; Tang, Hung‐Shang ‐S ; Sheeng, Tuzen‐Yan ‐Y ; Chen, Sung‐Chao ‐C ; Lee, San‐Kan ‐K ; Chung, Ping‐Hong ‐H. / Pharmacokinetics of promazine : I disposition in patients with acute viral hepatitis B. In: Biopharmaceutics & Drug Disposition. 1990 ; Vol. 11, No. 7. pp. 557-568.
@article{bcbb336edc704b88b92ddabe5c7d32ef,
title = "Pharmacokinetics of promazine: I disposition in patients with acute viral hepatitis B",
abstract = "Concentrations of promazine in plasma, plasma water, red blood cells, and urine were measured after oral administration of the drug to six patients during and after apparent recovery from the acute phase of viral hepatitis B. None of the promazine pharmacokinetic parameters were significantly different during and after the acute phase; these parameters included clearance, free drug clearance, metabolic clearance, volume of distribution, distribution and elimination half‐life values, plasma protein binding, and per cent excreted in the urine. During the acute period of the illness, SGOP, SGPT, alkaline phosphatase, and total bilirubin were increased in all patients; they returned to within or near the upper limits or normal after recovery. Despite the unchanged promazine disposition, four out of six patients had more severe promazine side‐effects, such as sedation, postural hypotension, and dizziness during the acute phase of the illness. This study suggests that promazine disposition was not significantly altered as a consequence of viral hepatitis. However, the pharmoacodynamic effects of promazine were changed significantly. Care must be taken with patients who are taking promazine during the acute phase of viral hepatitis B.",
keywords = "Acute viral hepatitis, Pharmacokinetics, Promazine",
author = "Hu, {Oliver Y.‐P} and Tang, {Hung‐Shang ‐S} and Sheeng, {Tuzen‐Yan ‐Y} and Chen, {Sung‐Chao ‐C} and Lee, {San‐Kan ‐K} and Chung, {Ping‐Hong ‐H}",
year = "1990",
month = "1",
day = "1",
doi = "10.1002/bdd.2510110702",
language = "English",
volume = "11",
pages = "557--568",
journal = "Biopharmaceutics and Drug Disposition",
issn = "0142-2782",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of promazine

T2 - I disposition in patients with acute viral hepatitis B

AU - Hu, Oliver Y.‐P

AU - Tang, Hung‐Shang ‐S

AU - Sheeng, Tuzen‐Yan ‐Y

AU - Chen, Sung‐Chao ‐C

AU - Lee, San‐Kan ‐K

AU - Chung, Ping‐Hong ‐H

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Concentrations of promazine in plasma, plasma water, red blood cells, and urine were measured after oral administration of the drug to six patients during and after apparent recovery from the acute phase of viral hepatitis B. None of the promazine pharmacokinetic parameters were significantly different during and after the acute phase; these parameters included clearance, free drug clearance, metabolic clearance, volume of distribution, distribution and elimination half‐life values, plasma protein binding, and per cent excreted in the urine. During the acute period of the illness, SGOP, SGPT, alkaline phosphatase, and total bilirubin were increased in all patients; they returned to within or near the upper limits or normal after recovery. Despite the unchanged promazine disposition, four out of six patients had more severe promazine side‐effects, such as sedation, postural hypotension, and dizziness during the acute phase of the illness. This study suggests that promazine disposition was not significantly altered as a consequence of viral hepatitis. However, the pharmoacodynamic effects of promazine were changed significantly. Care must be taken with patients who are taking promazine during the acute phase of viral hepatitis B.

AB - Concentrations of promazine in plasma, plasma water, red blood cells, and urine were measured after oral administration of the drug to six patients during and after apparent recovery from the acute phase of viral hepatitis B. None of the promazine pharmacokinetic parameters were significantly different during and after the acute phase; these parameters included clearance, free drug clearance, metabolic clearance, volume of distribution, distribution and elimination half‐life values, plasma protein binding, and per cent excreted in the urine. During the acute period of the illness, SGOP, SGPT, alkaline phosphatase, and total bilirubin were increased in all patients; they returned to within or near the upper limits or normal after recovery. Despite the unchanged promazine disposition, four out of six patients had more severe promazine side‐effects, such as sedation, postural hypotension, and dizziness during the acute phase of the illness. This study suggests that promazine disposition was not significantly altered as a consequence of viral hepatitis. However, the pharmoacodynamic effects of promazine were changed significantly. Care must be taken with patients who are taking promazine during the acute phase of viral hepatitis B.

KW - Acute viral hepatitis

KW - Pharmacokinetics

KW - Promazine

UR - http://www.scopus.com/inward/record.url?scp=0025107775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025107775&partnerID=8YFLogxK

U2 - 10.1002/bdd.2510110702

DO - 10.1002/bdd.2510110702

M3 - Article

VL - 11

SP - 557

EP - 568

JO - Biopharmaceutics and Drug Disposition

JF - Biopharmaceutics and Drug Disposition

SN - 0142-2782

IS - 7

ER -